Organisation paid for research Program year 2021 Source: CMS Open Payments

Texas Dermatology

Neither a doctor nor a teaching hospital

Research payments

$2,279,869

15 payments

Through program year 2021, Texas Dermatology is reported as receiving $2,279,869 in research payments, across 15 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$4,712	1
2020	Research	$785,039	8
2019	Research	$1,490,118	6

Breakdown

Who paid Research payments · program years 2019–2021

Novartis Pharmaceuticals Corporation $2,257,171 10 payments
Regeneron Pharmaceuticals, Inc. $19,385 4 payments
Bausch Health US, LLC $3,313 1 payment

Studies the money was for Research payments · program years 2019–2021

A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $1,000,564 2 payments
Pediatric Study in Children With Moderate to Severe Plaque Psoriasis $658,749 2 payments
A Randomized Double Blind Placebo and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept in A Single Blinded Arm After Twelve Weeks of Treatment and to Assess the Safety Tolerability $481,721 2 payments
Multicenter Randomized Double Blind Placebo Controlled 52 Week Study to Demonstrate the Efficacy Safety and Tolerability of Secukinumab Injections With 2 ML Auto Injectors 300 MG in Adult Subjects With Plaque Psoriasis $114,274 2 payments
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis $19,385 4 payments
Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $3,313 1 payment
A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study to Determine the Efficacy and Safety of Oral Zpl389a 3 MG 10 MG 30 MG and 50 MG Capsules Administered for 16 Weeks in Subjects With Moderate to Severe Atopic Dermatitis $1,862 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.